Press "Enter" to skip to content

Osimertinib at Lower Dose Effective in EGFR-Mutant NSCLC With Leptomeningeal Metastases – OncLive

admin 0

Osimertinib at Lower Dose Effective in EGFR-Mutant NSCLC With Leptomeningeal Metastases  OncLive

Osimertinib (Tagrisso) at a once-daily dose of 80 mg demonstrated similar signs of activity, as well as a clinically meaningful benefit in patients with EGFR …

“lung cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *